 Monica Grazziutti
Concepts (175)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transplantation Conditioning | 2 | 2013 | 89 | 0.830 |
Why?
| | Multiple Myeloma | 14 | 2017 | 2714 | 0.710 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2013 | 532 | 0.700 |
Why?
| | Neutropenia | 4 | 2012 | 116 | 0.540 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2013 | 26 | 0.530 |
Why?
| | Melphalan | 3 | 2016 | 176 | 0.480 |
Why?
| | Mannans | 5 | 2011 | 20 | 0.430 |
Why?
| | Aspergillosis | 4 | 2010 | 117 | 0.340 |
Why?
| | Stomatitis | 1 | 2006 | 19 | 0.330 |
Why?
| | Myeloablative Agonists | 1 | 2006 | 35 | 0.330 |
Why?
| | Reticulocyte Count | 1 | 2006 | 7 | 0.320 |
Why?
| | Neutrophils | 1 | 2006 | 163 | 0.290 |
Why?
| | Invasive Pulmonary Aspergillosis | 2 | 2012 | 13 | 0.240 |
Why?
| | Lymphocyte Activation | 2 | 1998 | 213 | 0.210 |
Why?
| | Aspergillus | 3 | 2010 | 50 | 0.200 |
Why?
| | Aspergillus fumigatus | 2 | 1998 | 63 | 0.200 |
Why?
| | Transplantation, Autologous | 4 | 2014 | 459 | 0.200 |
Why?
| | Thalidomide | 2 | 2016 | 406 | 0.200 |
Why?
| | Th1 Cells | 1 | 1997 | 49 | 0.180 |
Why?
| | Cytokines | 2 | 1998 | 683 | 0.170 |
Why?
| | Prognosis | 8 | 2017 | 2077 | 0.170 |
Why?
| | Aged | 14 | 2017 | 10169 | 0.160 |
Why?
| | Hematologic Neoplasms | 2 | 2008 | 89 | 0.160 |
Why?
| | Immunoglobulin Light Chains | 1 | 2017 | 98 | 0.160 |
Why?
| | Neoplasm, Residual | 1 | 2017 | 173 | 0.160 |
Why?
| | Middle Aged | 15 | 2017 | 13329 | 0.150 |
Why?
| | Creatinine | 2 | 2012 | 164 | 0.150 |
Why?
| | Retrospective Studies | 8 | 2014 | 5788 | 0.140 |
Why?
| | Predictive Value of Tests | 3 | 2007 | 1051 | 0.140 |
Why?
| | Humans | 25 | 2017 | 51226 | 0.140 |
Why?
| | Male | 16 | 2017 | 27647 | 0.130 |
Why?
| | Adult | 13 | 2017 | 14064 | 0.130 |
Why?
| | Systole | 1 | 2014 | 79 | 0.130 |
Why?
| | Central Nervous System Neoplasms | 1 | 2013 | 50 | 0.130 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 165 | 0.130 |
Why?
| | Amyloidosis | 1 | 2014 | 81 | 0.130 |
Why?
| | Galactose | 5 | 2011 | 32 | 0.120 |
Why?
| | Female | 14 | 2017 | 28342 | 0.120 |
Why?
| | Survival Analysis | 5 | 2017 | 789 | 0.120 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 85 | 0.120 |
Why?
| | Platelet Count | 1 | 2012 | 77 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2016 | 1013 | 0.110 |
Why?
| | Serum | 1 | 2011 | 40 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2011 | 90 | 0.110 |
Why?
| | Renal Insufficiency | 1 | 2012 | 136 | 0.110 |
Why?
| | Mucositis | 1 | 2010 | 12 | 0.110 |
Why?
| | Paranasal Sinuses | 1 | 2010 | 24 | 0.110 |
Why?
| | Aged, 80 and over | 6 | 2017 | 3550 | 0.110 |
Why?
| | Kidney Diseases | 2 | 2017 | 281 | 0.100 |
Why?
| | Lung | 2 | 2010 | 488 | 0.100 |
Why?
| | Treatment Outcome | 7 | 2017 | 5480 | 0.100 |
Why?
| | Kidney | 2 | 2012 | 763 | 0.100 |
Why?
| | Stem Cell Transplantation | 2 | 2007 | 194 | 0.090 |
Why?
| | Antigens, Fungal | 1 | 2007 | 30 | 0.090 |
Why?
| | Lung Diseases, Fungal | 1 | 2007 | 33 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 2 | 1998 | 136 | 0.080 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2007 | 62 | 0.080 |
Why?
| | Lactoperoxidase | 1 | 2006 | 4 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2016 | 522 | 0.080 |
Why?
| | Glucose Oxidase | 1 | 2006 | 6 | 0.080 |
Why?
| | Incidence | 2 | 2010 | 1083 | 0.080 |
Why?
| | Professional Misconduct | 1 | 2006 | 7 | 0.080 |
Why?
| | Muramidase | 1 | 2006 | 16 | 0.080 |
Why?
| | Ethics, Research | 1 | 2006 | 40 | 0.080 |
Why?
| | Iron Overload | 1 | 2006 | 12 | 0.080 |
Why?
| | Drug Combinations | 1 | 2006 | 131 | 0.080 |
Why?
| | Soft Tissue Infections | 1 | 2005 | 13 | 0.080 |
Why?
| | Tomography, Emission-Computed | 1 | 2005 | 71 | 0.080 |
Why?
| | Models, Statistical | 1 | 2007 | 256 | 0.080 |
Why?
| | Joint Diseases | 1 | 2005 | 45 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2006 | 200 | 0.070 |
Why?
| | Regression Analysis | 1 | 2006 | 475 | 0.070 |
Why?
| | Metaphase | 2 | 2016 | 57 | 0.070 |
Why?
| | Recovery of Function | 1 | 2006 | 233 | 0.070 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 136 | 0.070 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2005 | 201 | 0.070 |
Why?
| | Kinetics | 1 | 2006 | 724 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2005 | 253 | 0.070 |
Why?
| | Risk Factors | 3 | 2010 | 3924 | 0.070 |
Why?
| | Neoplasms | 2 | 2007 | 1158 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2006 | 1077 | 0.060 |
Why?
| | Multivariate Analysis | 3 | 2012 | 688 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1556 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2007 | 1084 | 0.060 |
Why?
| | Interleukin-2 | 2 | 1998 | 81 | 0.060 |
Why?
| | Plasma Cells | 2 | 2013 | 225 | 0.060 |
Why?
| | Cohort Studies | 1 | 2006 | 1485 | 0.060 |
Why?
| | Interferon-gamma | 2 | 1998 | 196 | 0.050 |
Why?
| | Time Factors | 3 | 2017 | 3392 | 0.050 |
Why?
| | Bordetella bronchiseptica | 1 | 1998 | 1 | 0.050 |
Why?
| | Bordetella Infections | 1 | 1998 | 2 | 0.050 |
Why?
| | Opportunistic Infections | 1 | 1998 | 59 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 1997 | 15 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 1998 | 26 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 1997 | 52 | 0.040 |
Why?
| | Candida albicans | 1 | 1997 | 30 | 0.040 |
Why?
| | Interleukin-4 | 1 | 1997 | 49 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1997 | 77 | 0.040 |
Why?
| | Lymphocytes | 1 | 1998 | 175 | 0.040 |
Why?
| | Flow Cytometry | 2 | 1998 | 583 | 0.040 |
Why?
| | Leukemia | 1 | 1998 | 75 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 1997 | 96 | 0.040 |
Why?
| | Coculture Techniques | 1 | 1997 | 162 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2017 | 65 | 0.040 |
Why?
| | Interleukin-10 | 1 | 1997 | 107 | 0.040 |
Why?
| | Mycoses | 1 | 1998 | 154 | 0.040 |
Why?
| | Dendritic Cells | 1 | 1998 | 148 | 0.040 |
Why?
| | Cells, Cultured | 2 | 1998 | 1828 | 0.040 |
Why?
| | Antigens, CD | 1 | 1997 | 264 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1997 | 430 | 0.040 |
Why?
| | Bone Marrow | 1 | 2017 | 410 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2016 | 309 | 0.040 |
Why?
| | Biopsy | 1 | 2017 | 690 | 0.040 |
Why?
| | Myocardium | 1 | 2017 | 460 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 35 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 380 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2014 | 103 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2013 | 1658 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 880 | 0.030 |
Why?
| | Risk Assessment | 1 | 2017 | 1395 | 0.030 |
Why?
| | Recurrence | 1 | 2013 | 690 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2012 | 130 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2012 | 160 | 0.030 |
Why?
| | Body Surface Area | 1 | 2010 | 25 | 0.030 |
Why?
| | Pyrazines | 1 | 2012 | 205 | 0.030 |
Why?
| | Boronic Acids | 1 | 2012 | 201 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 249 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2013 | 799 | 0.030 |
Why?
| | Enteritis | 1 | 2010 | 17 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 456 | 0.030 |
Why?
| | Databases, Factual | 1 | 2013 | 685 | 0.030 |
Why?
| | Prospective Studies | 1 | 2016 | 2395 | 0.030 |
Why?
| | Colitis | 1 | 2010 | 58 | 0.030 |
Why?
| | Radiography | 1 | 2010 | 539 | 0.020 |
Why?
| | Disease Progression | 1 | 2012 | 879 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2008 | 38 | 0.020 |
Why?
| | Cytogenetic Analysis | 1 | 2007 | 78 | 0.020 |
Why?
| | Ethics Committees, Research | 1 | 2006 | 15 | 0.020 |
Why?
| | Los Angeles | 1 | 2006 | 25 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 83 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 2006 | 41 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2007 | 99 | 0.020 |
Why?
| | Echinocandins | 1 | 2006 | 46 | 0.020 |
Why?
| | Drug Approval | 1 | 2006 | 46 | 0.020 |
Why?
| | Lipopeptides | 1 | 2006 | 50 | 0.020 |
Why?
| | Chromosome Deletion | 1 | 2007 | 147 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2007 | 273 | 0.020 |
Why?
| | Research | 1 | 2006 | 114 | 0.020 |
Why?
| | Medical Records | 1 | 2005 | 96 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 532 | 0.020 |
Why?
| | Dexamethasone | 1 | 2007 | 399 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2007 | 703 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2007 | 268 | 0.020 |
Why?
| | Patient Selection | 1 | 2006 | 293 | 0.020 |
Why?
| | Angiogenesis Inhibitors | 1 | 2006 | 212 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2006 | 664 | 0.020 |
Why?
| | Brain | 1 | 2013 | 1429 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2006 | 315 | 0.020 |
Why?
| | Adolescent | 2 | 2007 | 6735 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 2403 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2005 | 763 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1998 | 14 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1998 | 43 | 0.010 |
Why?
| | Leukocyte Transfusion | 1 | 1998 | 12 | 0.010 |
Why?
| | Colony-Stimulating Factors | 1 | 1998 | 11 | 0.010 |
Why?
| | Immunomagnetic Separation | 1 | 1998 | 10 | 0.010 |
Why?
| | Scattering, Radiation | 1 | 1998 | 28 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1998 | 186 | 0.010 |
Why?
| | Adjuvants, Immunologic | 1 | 1998 | 64 | 0.010 |
Why?
| | Light | 1 | 1998 | 74 | 0.010 |
Why?
| | Reference Values | 1 | 1998 | 389 | 0.010 |
Why?
| | Acute Disease | 1 | 1998 | 409 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1998 | 399 | 0.010 |
Why?
| | United States | 1 | 2006 | 4931 | 0.010 |
Why?
| | Phenotype | 1 | 1998 | 814 | 0.010 |
Why?
|
|
Grazziutti's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|